中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | HB188016 |
|---|---|
| 説明 |
Monalizumab (HB188016) is a research-grade recombinant antibody targeting CD159. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 種反応性 | Human |
| アプリケーション | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | IgG4-kappa |
| 発現システム | Mammalian cells |
| ターゲット | KLRC1, NKG2-A/NKG2-B type II integral membrane protein, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, CD159a, NK cell receptor A, NKG2A |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% purity as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | P26715 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | IPH-2201, NN-8765, NNC-0141-0000-0100, NNC-141-01000, monolizumab, anti-NKG2A, humZ270, 1228763-95-8 |
| 背景 | NKG2-A/NKG2-B type II integral membrane protein (CD159a/KLRC1) is a ~26 kDa protein. Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self. Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules. Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions. 1. Sullivan, LC. et al. (2007) Immunity 27, 900-11. PMID: 18083576 2. Lin, Z. et al. (2023) Nature immunology 24, 1087-1097. PMID: 37264229 3. Valiante, NM. et al. (1997) Immunity 7, 739-51. PMID: 9430220 4. Braud, VM. et al. (1998) Nature 391, 795-9. PMID: 9486650 5. Kabat, J. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 169, 1948-58. PMID: 12165520 6. Le Dréan, E. et al. (1998) European journal of immunology 28, 264-76. PMID: 9485206 7. Kamiya, T. et al. (2019) The Journal of clinical investigation 129, 2094-2106. PMID: 30860984 8. Jabri, B. et al. (2002) Immunity 17, 487-99. PMID: 12387742 9. Bhagat, G. et al. (2008) The Journal of clinical investigation 118, 281-93. PMID: 18064301 |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107) |
SDS-PAGE for Research Grade Monalizumab.
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
